Skip to content
Evigrade
ModerateTestosterone 5α-reductase types 1 and 2 inhibitors×Calcineurin inhibitor (immunosuppressant)

Updated · Methodology

Mechanism

Dutasteride is extensively metabolised by CYP3A4 and CYP3A5 and is more than 99.5% bound to plasma proteins (dutasteride SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Tacrolimus inhibits CYP3A4, and according to its SmPC it may affect the metabolism of drugs metabolised by this enzyme. Tacrolimus itself is more than 98.8% bound to plasma proteins, and its SmPC advises considering possible interactions with other highly protein-bound drugs (tacrolimus SmPCs, AEMPS and European Medicines Agency, EMA). The documents do not state how strongly tacrolimus inhibits CYP3A4. With the moderate CYP3A4 inhibitors verapamil and diltiazem, dutasteride levels were on average 1.6–1.8 times higher (tacrolimus SmPC, AEMPS, and Prograf label, US Food and Drug Administration, FDA; dutasteride SmPC, AEMPS). Dutasteride itself does not inhibit CYP3A4 or P-glycoprotein, the pathways through which other drugs raise tacrolimus levels (dutasteride and tacrolimus SmPCs, AEMPS).

Symptoms

The documents describe no symptoms of this combination. According to the dutasteride SmPC, no further 5-alpha reductase inhibition is expected when dutasteride exposure rises. The most common adverse effects of dutasteride are impotence, decreased libido, ejaculation disorders and breast disorders (dutasteride SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Tacrolimus very commonly causes tremor, impaired kidney function, high blood glucose and potassium, hypertension and insomnia, and commonly hair loss. Higher tacrolimus blood levels raise the risk of serious adverse reactions, including kidney toxicity, neurotoxicity and QT prolongation (tacrolimus SmPC, AEMPS).

Management

No document names the pair, but by its own documents dutasteride belongs to two classes in the tacrolimus SmPC: drugs metabolised by CYP3A4 and drugs highly bound to plasma proteins (tacrolimus SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS, and European Medicines Agency, EMA; dutasteride SmPC, AEMPS). For highly protein-bound drugs, the tacrolimus SmPC says to monitor tacrolimus trough blood levels and adjust the tacrolimus dose if necessary (tacrolimus SmPC, AEMPS). The dutasteride dose is not changed in advance. The dutasteride documents call for caution only with long-term use of strong CYP3A4 inhibitors, and the tacrolimus documents do not describe tacrolimus as a strong inhibitor (dutasteride SmPC, AEMPS, and Avodart label, US Food and Drug Administration, FDA; tacrolimus SmPC, AEMPS, and Prograf label, FDA). If dutasteride metabolism is inhibited, its long half-life may become even longer, and reaching a new steady state may take more than 6 months of combined use (dutasteride SmPC, AEMPS). CYP3A4 inhibitors and inducers are given with tacrolimus only after consulting a transplant specialist. Dutasteride does not inhibit CYP3A4 or P-glycoprotein (tacrolimus and dutasteride SmPCs, AEMPS). Dutasteride is contraindicated in severe hepatic impairment and is used with caution in mild to moderate hepatic impairment (dutasteride SmPC, AEMPS).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dutasteride

Other interactions with Tacrolimus